As the popularity of GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) continues to grow, so too does the conversation around their aesthetic side effects. The term “Ozempic face” has made headlines, but behind the catchy label lies a genuine clinical concern: significant facial volume loss, sagging, and dullness resulting from both rapid weight loss and underlying cellular changes in the skin.
While public discussions often stop at the visible symptoms, dermatologists are now unpacking the science — and using an opportunity to play a more integral role in the multidisciplinary care of GLP-1 patients.
The Science Behind the Change
GLP-1 therapy affects more than the number on the scale. Beyond fat loss, researchers note that these drugs can influence adipocyte-derived stem cells (ADSCs), impairing collagen and elastin synthesis and reducing hyaluronic acid production. This accelerates the appearance of skin laxity and volume depletion, particularly in patients already predisposed by age, genetics, or other health factors.
The speed of weight loss matters. When fat volume decreases too quickly, the skin often cannot remodel at the same pace. This mismatch creates the hollowed or sagging appearance associated with “Ozempic face,” making intervention strategies increasingly important in dermatology practice.
Preventive and Restorative Approaches
Patient education is emerging as a cornerstone of effective care. Experts recommend initiating conversations about skin health at the same time as discussions about nutrition and exercise — ideally before patients start GLP-1 therapy.
In some cases, microdosing GLP-1s to slow weight loss may give the skin more time to adapt. From a procedural standpoint, injectables like Sculptra and Restylane products are proving valuable, not only in restoring lost volume but also in stimulating new collagen production and improving hydration.
A Growing Role for Dermatology in GLP-1 Care
The surge in GLP-1 prescriptions represents more than just a medical trend — it’s an inflection point for the aesthetics industry. Dermatologists who proactively address the skin-related effects of these drugs are not only meeting a growing patient need but also expanding their scope of influence in a competitive landscape.
With a patient base that is already motivated to invest in their health and appearance, GLP-1 therapy recipients may represent one of the most engaged demographics for long-term dermatologic care. This underscores the importance of cross-specialty collaboration and early intervention strategies to maintain both skin integrity and patient confidence.
